ICD-10 Coding for Hematology
Hematology ICD-10 coding draws primarily from the D chapter (diseases of the blood and blood-forming organs, D50-D89), the C chapter (malignant neoplasms of lymphoid and hematopoietic tissue, C81-C96), and the Z chapter (encounter codes for chemotherapy and transfusion services). The specificity requirements for hematologic malignancies are extensive because the ICD-10 codes distinguish between disease type, cell lineage, achievement of remission, and relapse status. Accurate diagnosis coding directly affects drug authorization because payers use the ICD-10 code to verify that the prescribed treatment matches the diagnosed condition.
Hematologic Malignancy Codes (C81-C96)
Lymphoma codes require specification of type and site. Hodgkin lymphoma (C81) is subdivided by histologic type: C81.0 (nodular lymphocyte predominant), C81.1 (nodular sclerosis), C81.2 (mixed cellularity), C81.3 (lymphocyte depleted), C81.4 (lymphocyte-rich), C81.7 (other), C81.9 (unspecified). Non-Hodgkin lymphoma codes include diffuse large B-cell (C83.3), follicular (C82.0-C82.9), and mantle cell (C83.1), each with site specification. Leukemia codes: C91.10 (CLL not in remission), C91.11 (CLL in remission), C91.12 (CLL in relapse); C92.00 (AML not in remission), C92.01 (AML in remission), C92.02 (AML in relapse). The remission status (not in remission, in remission, in relapse) must be updated with each clinical reassessment because it affects treatment decisions and drug authorization.
Benign Hematologic Condition Codes (D50-D89)
Anemia codes require specificity of type and cause. D50.0 (iron deficiency anemia secondary to blood loss) supports iron infusion therapy. D50.9 (iron deficiency anemia, unspecified) is less specific and may trigger medical necessity review for iron infusion. D51 (vitamin B12 deficiency anemia) supports B12 injection billing. D61.9 (aplastic anemia, unspecified) and D61.01 (constitutional aplastic anemia) affect treatment approach documentation. Coagulation disorders: D68.0 (von Willebrand disease), D68.1 (hereditary factor XI deficiency), D68.2 (hereditary deficiency of other clotting factors). Thrombocytopenia: D69.3 (immune thrombocytopenic purpura), D69.6 (thrombocytopenia, unspecified). Neutropenia: D70.0 (congenital agranulocytosis), D70.1 (agranulocytosis secondary to cancer chemotherapy), D70.9 (neutropenia, unspecified).
Encounter and Treatment Codes
Z51.11 (encounter for antineoplastic chemotherapy) is the primary encounter code when the visit purpose is chemotherapy administration. Z51.12 (encounter for antineoplastic immunotherapy) covers immunotherapy administration. Z51.0 (encounter for antineoplastic radiation therapy) covers radiation therapy visits. These Z codes are used as secondary diagnosis codes alongside the primary disease code. For example, a CLL patient receiving chemotherapy uses C91.10 as the primary diagnosis and Z51.11 as the secondary. Z51.11 signals to the payer that the visit involves chemotherapy administration and triggers the appropriate administration code edits. For transfusion encounters, use the specific anemia code as primary and Z51.81 (encounter for therapeutic drug monitoring) or the transfusion-specific diagnosis as supporting codes.
J-Code Reference for Common Hematology Drugs
Chemotherapy J-codes frequently used in hematology include: J9035 (bevacizumab, per 10 mg), J9041 (bortezomib, per 0.1 mg), J9145 (daratumumab, per 10 mg), J9228 (ipilimumab, per 1 mg), J9271 (pembrolizumab, per 1 mg), J9299 (nivolumab, per 1 mg), J9310 (rituximab, per 100 mg), and J9395 (venetoclax, oral, see specific code). Biosimilar products have separate J-codes: J9311 (rituximab-abbs, biosimilar), J9312 (rituximab-pvvr, biosimilar). Using the wrong J-code (reference biologic code for a biosimilar or vice versa) triggers denials. Supportive care drugs: J0881 (darbepoetin alfa, per 1 mcg), J0885 (epoetin alfa, per 1000 units), J1756 (iron sucrose, per 1 mg), J1439 (ferric carboxymaltose, per 1 mg), J1459 (IVIG, per 500 mg). Verify J-code updates quarterly because new drugs and biosimilars receive new codes regularly.
Documentation Standards for Hematology
Infusion documentation must include: drug name (generic and brand), dose administered (in mg or units), route (IV infusion, IV push, subcutaneous, intramuscular), infusion start time and stop time (for each drug separately), total infusion duration, pre-medications administered with times, hydration administered with independent start/stop times, adverse reactions (including grade per CTCAE if applicable), and nurse signature. For bone marrow biopsy, document the site (posterior iliac crest is standard), technique (Jamshidi needle or equivalent), number of cores obtained, aspiration adequacy (number of spicules), and any complications. For E/M visits with chemotherapy, clearly separate the E/M documentation from the treatment administration documentation to support modifier 25 when billing both on the same day.
Compliance Considerations
Hematology faces heightened compliance scrutiny because of the high dollar values involved in drug billing. The OIG has identified oncology/hematology drug billing as a focus area for fraud and abuse investigation. Key compliance risks include: billing for drugs not actually administered, billing for higher doses than administered, unbundling bone marrow biopsy and aspiration (billing 38220 + 38221 instead of 38222), billing hydration that ran concurrently with chemotherapy (not independently), and billing E/M visits on treatment days when no separately identifiable evaluation occurred. Conduct quarterly audits of drug billing (J-code units versus treatment records) and administration billing (codes versus infusion timelines) to identify discrepancies before they become compliance issues.